News >

Atezolizumab Shows Comparable Real-World Tolerability, Efficacy in Urothelial Carcinoma

Gina Columbus @ginacolumbusonc
Published: Monday, Mar 18, 2019

Dr. Sandra Horning

Sandra Horning, MD
Atezolizumab (Tecentriq) demonstrated consistent safety and efficacy with prior studies of the PD-L1 inhibitor in patients with locally advanced or metastatic urothelial carcinoma (mUC), including clinically relevant subgroups reflective of real-world clinical practice, according to results from the phase IIIb SAUL study, which were presented at the 2019 European Association of Urology Meeting.

Roche to Present Results of the Largest Safety Study of its Kind With Tecentriq (Atezolizumab) In Patients With Metastatic Bladder Cancer. Genentech (Roche). Published March 18, 2019. Accessed March 18, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication